1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 43,79€ (+139,29%). The median is 42,93€ (+134,59%).
| Buy |
18 |
| Hold |
1 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 8.62m | 84,06% |
| Gross profit | 8.62m | 84,06% |
| Net profit | −33.76m | 246,07% |
| EBITDA | −24.02m | 2.735,54% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 170.27m€ |
Number of shares | 9.68m |
52-week high/low | 37,65€ - 6,14€ |
| Dividends | No |
Beta | 1,52 |
P/E ratio | −1,18 |
PEG ratio | −0,04 |
P/B ratio | −3,29 |
P/S ratio | 4,34 |
Company profile
| Name | Sutro Biopharma |
| CEO | Jane Chung |
| Employees | 128 |
Discover assets
Shareholders of Sutro Biopharma also invest in the following assets
